Dr. Saeid Babaei Appointed Independent Board Member as Mydecine Moves Closer to NASDAQ Listing in Q1 2022 DENVER, Dec. 06, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full…

Source

Previous articlePsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug Administration
Next articlePsychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix Compounds